Sample6 develops point-of-need synthetic biology diagnostics and a cloud-based food safety management and control system for food processors across meat, seafood, dairy, produce, and dry goods. Its core product enables in-shift testing to detect and control pathogens at various points of need, and the software can integrate data from safety and laboratory management systems, including microbial and allergen testing. The company serves global customers such as Unilever, Smithfield, and Saputo. Led by newly appointed CEO Dr. Michael Koeris, Sample6 intends to use the funding to commercialize its food pathogen detection system for food safety. The company is based in Cambridge, MA. Total investment to date and operating metrics are reported in the financing coverage. Sample6 applies biotechnology to advance food safety, developing diagnostic assays and a software platform for the food industry. Its first products are Sample6 DETECT/L, a diagnostic assay designed to identify Listeria contamination, and Sample6 CONTROL, a software platform used to plan, execute, remediate and analyze food safety programs. The company intends to use the Series B proceeds to commercialize those products, which are expected to be available in the first half of 2014. Sample6 raised $11m in Series B financing to fund commercialization. The company is led by CEO Tim Curran. In conjunction with the funding, Canaan Partners added governance and scientific support through board and advisory appointments.

Total raised

$24M

Funding rounds

2

Latest round

Series C

Latest activity

Aug 2016